



ALLIA.143A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT RECEIVED
ES/10/16/01

OCT 03 2001

TECH CENTER 1600/2900

Applicant : H. Zaghouani

Appl. No. : 08/779,767

Filed : January 7, 1997

For : COMPOUNDS,
COMPOSITIONS AND
METHODS FOR THE
ENDOCYTIC
PRESENTATION OF
IMMUNOSUPPRESSIVE
FACTORS

Examiner : P. Nolan

) Group Art Unit 1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

September 20, 2001
(Date)

Daniel Hart, Reg. No. 40,637

10/03/2001 MBERHE 00000059 111410 08779767
02 FC:217 15.00 CH 445.00 DP

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed March 21, 2001, in the above-identified application, kindly amend the application as follows.

IN THE CLAIMS:

Please cancel claims (12 - 21, 25, 30 - 65, 75)

66. (previously amended three times) A composition comprising an immunoglobulin or a portion thereof linked to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor antagonist, said composition having the property of being endocytosed by cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist in association with endogenous MHC Class II molecules, thereby preventing T cell activation.